Oncology bispecific antibody trial starts by region

3 regions, 2020 to 2025

317 Global, 2025

Oncology bispecific antibody trial starts by region: 3 regions, 2020 to 2025Oncology bispecific antibody trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 23 to 489. Latest values: Global 317 (2025); China 153 (2025); United States 117 (2025). 0 100 200 300 400 500 2020 2021 2022 2023 2024 2025 Global China United States
Oncology bispecific antibody trial starts by region: 3 regions, 2020 to 2025Oncology bispecific antibody trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 23 to 489. Latest values: Global 317 (2025); China 153 (2025); United States 117 (2025). 0 200 400 600 2020 2021 2022 2023 2024 2025 Global China United States
Oncology bispecific antibody trial starts by region: 3 regions, 2020 to 2025Oncology bispecific antibody trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 23 to 489. Latest values: Global 317 (2025); China 153 (2025); United States 117 (2025). 0 200 400 600 2020 2021 2022 2023 2024 2025 Global China United States
View the underlying data
Oncology bispecific antibody trial starts by region: 3 regions, 2020 to 2025
Region Period Type Value
Global 2025 Actual 317
Global 2024 Actual 226
Global 2023 Actual 189
Global 2022 Actual 130
Global 2021 Actual 104
Global 2020 Actual 61
China 2025 Actual 153
China 2024 Actual 119
China 1 Jan 2023 to 27 Sep 2026 Actual 489
China 2022 Actual 64
China 2021 Actual 41
China 2020 Actual 23
United States 2025 Actual 117
United States 2024 Actual 78
United States 2023 Actual 62
United States 2022 Actual 64
United States 2021 Actual 58
United States 2020 Actual 32
Chart: StatOrigin · Source: ClinicalTrials.gov · statorigin.org CC BY 4.0